MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce the consolidation of its ownership covering a group of eight mining claims at the Mirage project pursuant to a purchase and sale agreement dated August 15, 2025, with General Partnership Osisko Baie James (“Osisko Baie James”). Brunswick Exploration now owns 100% of the mining claims across the Mirage project. To acquire such rights, Brunswick has ag ...

Core Insights - Allarity Therapeutics has successfully initiated enrollment in an advanced Phase 2 clinical trial for ovarian cancer, focusing on recurrent, platinum-resistant or platinum-ineligible patients [1][6] - The company has expanded its global intellectual property (IP) protection by securing an Australian patent for the stenoparib DRP companion diagnostic, which includes 40 claims [5] - A new service contract has been secured with a European biotech for Allarity Medical Laboratory, enhancing revenue opportunities [1][10] Clinical and Drug Development Progress - The Phase 2 clinical trial for stenoparib is progressing well, with initial patient dosing reflecting strong engagement from investigators [6] - A partnership has been initiated with the Indiana Biosciences Research Institute to conduct advanced studies on the anti-cancer effects of stenoparib, potentially expanding its therapeutic applications [6] - The company is also advancing a Veterans Administration-funded combination trial of stenoparib and temozolomide in small cell lung cancer, with patient recruitment expected to begin in the second half of 2025 [10] Financial Performance - As of June 30, 2025, Allarity reported cash and cash equivalents of $17.8 million, down from $19.5 million at the end of 2024 [16] - The company reduced its accounts payable and accrued expenses by $2 million during the quarter, indicating improved financial management [2][10] - Research and Development (R&D) expenses for the second quarter of 2025 were $2.3 million, compared to $1.06 million in the same quarter of 2024, reflecting ongoing clinical advancement activities [10][18] Corporate and Strategic Developments - Allarity has made significant progress in strengthening its leadership team, with new appointments to the Board of Directors and executive positions [10] - The company has launched a refined monotherapy trial protocol for stenoparib, which is now steadily enrolling patients [3][10] - Allarity's DRP platform has been expanded to include a new DRP for the antibody therapy daratumumab, showcasing its broad applicability across various cancer types [10]

Core Viewpoint - Graphjet Technology has announced a share consolidation at a ratio of 1-for-60, effective August 25, 2025, to increase the trading price of its ordinary shares to meet Nasdaq's listing requirements [1][6]. Group 1: Share Consolidation Details - The share consolidation will automatically combine every 60 ordinary shares into one ordinary share, with no effect on shareholders' percentage ownership, except for fractional shares [3][6]. - The par value of the ordinary shares will be increased from $0.0001 to $0.006 per share as part of the consolidation [1]. - The new CUSIP number for the ordinary shares post-consolidation will be G30449139 [2]. Group 2: Implementation and Process - The share consolidation will take effect at 12:01 a.m. Eastern Time on August 25, 2025, with trading on a split-adjusted basis commencing at the market open on the same day [2]. - Continental Stock Transfer & Trust Company will act as the exchange agent for the share consolidation, automatically adjusting positions for shareholders holding shares electronically [5]. - Fractional shares resulting from the consolidation will be rounded up to the nearest whole share, ensuring no fractional shares are issued [4]. Group 3: Company Background - Graphjet Technology, founded in 2019 in Malaysia, specializes in producing graphene and graphite using patented technology that recycles palm kernel shells [8]. - The company's sustainable production methods aim to transform the global graphite and graphene supply chain by utilizing waste agricultural products [8].

Group 1 - Smart Share Global Limited, also known as Energy Monster, received a preliminary non-binding proposal from Hillhouse Investment Management to acquire all outstanding ordinary shares not already owned by Hillhouse or Management Members for US$1.77 per ADS or US$0.885 per share in cash [1] - The Company had previously entered into a definitive Agreement and Plan of Merger with Trustar Mobile Charging Holdings Limited, which includes key Management Members [2] - A special committee of independent directors is evaluating all options for the best interests of shareholders with the help of independent financial and legal advisors [3] Group 2 - Smart Share Global Limited is the largest provider of mobile device charging services in China, holding the number one market share [5] - The Company operates a network of 9.6 million power banks located in 1,279,900 points of interest across over 2,200 counties and county-level districts in China as of December 31, 2024 [5]

Core Viewpoint - Ebang International Holdings Inc. reported a significant increase in total net revenues for the first half of fiscal year 2025, driven by growth in its Fintech and renewable energy sectors, despite facing a gross loss and net loss reduction compared to the previous year [2][4][9]. Financial Performance - Total net revenues for the first six months of 2025 were US$3.58 million, a 69.46% increase from US$2.11 million in the same period of 2024 [2][4]. - Gross loss was US$0.65 million in the first half of 2025, compared to a gross profit of US$0.08 million in the same period of 2024 [2][6]. - Net loss decreased to US$4.50 million in the first half of 2025 from US$6.65 million in the same period of 2024 [2][9]. - Basic and diluted net loss per share were both US$0.72, down from US$0.99 in the same period of 2024 [9]. Revenue and Cost Analysis - Revenue growth was attributed to increased sales of renewable energy products and services, as well as rental services initiated in the second half of 2024 [4]. - Cost of revenues rose to US$4.23 million, a 108.20% increase from US$2.03 million in the same period of 2024, primarily due to higher sales and a VAT recoverable impairment [5][6]. - Total operating expenses decreased to US$10.21 million from US$12.50 million in the same period of 2024, reflecting cost-saving measures [6][12]. Strategic Outlook - The company aims to leverage its expertise in chip technology and intelligent manufacturing to enhance its renewable energy initiatives, establishing a vertically integrated industrial ecosystem [3]. - Future plans include exploring technology demand in regulated Fintech markets and expanding "Made in America" manufacturing capabilities [3]. - The company is committed to adapting to market demands and pursuing new opportunities in both Fintech and renewable energy sectors [10].

Core Viewpoint - InnovAge Holding Corp. has announced a joint venture with Tampa General Hospital to enhance community-based care options for seniors in the Tampa Bay area, focusing on improving access to quality care for clinically frail and underserved seniors [1][2]. Company Overview - InnovAge is a leader in senior care through the Program of All-Inclusive Care for the Elderly (PACE), aiming to help seniors live independently at home while receiving necessary healthcare and support [1][5]. - As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states [6]. Joint Venture Details - The joint venture aims to expand innovative community-based care options and improve access to quality care for seniors in Hillsborough, Pasco, and Hernando counties [2]. - The InnovAge Florida PACE center in Tampa has a 35,000-square-foot facility capable of serving around 1,300 seniors, offering a range of services including primary and specialty medical care, dental services, rehabilitation therapies, and social activities [4]. Tampa General Hospital Overview - Tampa General Hospital is recognized as the 1 hospital in the Tampa Bay region for the 10th consecutive year and is noted for its excellence in geriatrics [3]. - The hospital is a not-for-profit academic health system with 1,529 beds and is the only center for Level 1 trauma and comprehensive burn care in the region [7]. - In fiscal year 2023, Tampa General provided a net community benefit of approximately $301.8 million, supporting underinsured patients and community health organizations [8].

Core Insights - Foresight Autonomous Holdings Ltd. reported financial results for Q2 and the first half of 2025, highlighting progress in commercial agreements and technological advancements in 3D perception systems [1][4][6]. Second Quarter Corporate Highlights - Revenues for Q2 2025 were $128,000, a slight increase from $123,000 in Q2 2024, primarily driven by agreements with Elbit Systems and successful testing with Software République [6]. - The company signed a $12 million commercialization agreement with Zhejiang StreamRail for urban rail transit integration, with expected deployment in 2026 [7]. - A collaboration with a Tier-One automotive supplier aims to enhance bus safety using Foresight's technology, with proof-of-concept testing ongoing in H2 2025 [7]. First Half 2025 Corporate Highlights - Total revenues for the first half of 2025 reached $240,000, compared to $224,000 in the same period of 2024 [9]. - Research and development expenses decreased by 2.2% to $4,426,000, while sales and marketing expenses increased by 9.2% to $629,000 [9]. - General and administrative expenses rose by 11.6% to $1,296,000, mainly due to increased share-based compensation [9]. Financial Performance - GAAP net loss for Q2 2025 was $2,815,000, improving from a loss of $3,172,000 in Q2 2024 [9]. - Non-GAAP net loss for Q2 2025 was $2,598,000, compared to $3,030,000 in Q2 2024 [10]. - For the first half of 2025, GAAP net loss was $6,095,000, compared to $4,708,000 in the first half of 2024 [10]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $6,392,000, down from $7,182,000 at the end of 2024 [18]. - Total equity decreased by 16.4% to $5,625,000, primarily due to the net loss for the period [18]. Technological Developments - Foresight enhanced its perception systems by integrating NVIDIA Jetson Orin platforms, significantly improving AI processing capabilities for automotive and drone applications [7]. - Eye-Net Mobile made significant strides in V2X safety, completing a paid proof-of-concept with a major European OEM and achieving successful trial results in France [5].

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider. In connection with the private placement, the manager of the private placement, IDEX Biometrics and Mr. Storbråten entered into a share lending agreement. Mr. Storbråten has lent 4,359,315 shares, in connection with the settlement of Tranche 2. The shares have been lent, not sold ...

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), an official TSA PreCheck® enrollment provider, is making it easier and more affordable for travelers to get through security faster. As part of the Transportation Security Administration’s (TSA) Families on the Fly campaign, CLEAR is offering a limited-time Buy One, Get One $15 Off promotion for TSA PreCheck® enrollment when two family members sign up together. From now through October 31, 2025, new applicants who enroll together at the same enr ...

Company Overview - YD Biopharma Limited is a clinical-stage biopharmaceutical company focused on cancer prevention medical diagnostics and the development of exosome-based therapeutics aimed at addressing diseases with high unmet medical needs [6] - The company has established itself as a recognized supplier of clinical trial drugs and is also developing post-market auxiliary products [6] Business Combination Details - Breeze Holdings Acquisition Corp. announced the approval of its business combination with YD Biopharma, with stockholders voting overwhelmingly in favor (3,127,474 shares for, 1,000 against, and 21 abstentions) [3] - The combined entity will operate under the name YD Bio Limited and is expected to trade on Nasdaq with the ticker symbol "YDES" [4] - The transaction is anticipated to close within the next two weeks, pending customary closing conditions [4] Advisors Involved - Legal and financial advisors for the transaction include ArentFox Schiff LLP for YD Biopharma, I-Bankers Securities, Inc. for Breeze, and Woolery & Co. PLLC for Breeze [5]